Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6043 in Advanced/Metastatic Solid Tumors
NCT07424547Phase 1Recruiting
- Sponsor
- Conjupro Biotherapeutics, Inc.
- Start
- Mar 2026
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of SYS6043 in solid tumor, small cell lung cancer (SCLC), breast cancer and 2 more (3 arms), sponsored by Conjupro Biotherapeutics, Inc. Primary endpoints: Maximum Tolerated Dose at 1 year, Recommended Phase II Dose at 1 year and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
SYS6043
03
Conditions
solid tumorsmall cell lung cancer (SCLC)breast cancerprostate cancer (PCa)ovarian cancer
Beyond the preview
Go deeper on NCT07424547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07424547.